Arrowhead Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Arrowhead Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 23.4% bzw. 51.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 24.8% pro Jahr wachsen soll.

Wichtige Informationen

21.0%

Wachstumsrate der Gewinne

23.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.2%
Wachstumsrate der Einnahmen	52.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Jun 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ARWR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2026	231	-456	-546	-311	10
9/30/2025	151	-504	-444	-338	16
9/30/2024	62	-537	-617	-479	16
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	152	157	N/A
3/31/2019	95	10	130	132	N/A
12/31/2018	47	-29	134	136	N/A
9/30/2018	16	-54	-49	-47	N/A
6/30/2018	14	-54	-55	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A
9/30/2014	0	-59	N/A	-35	N/A
6/30/2014	0	-50	N/A	-30	N/A
3/31/2014	0	-44	N/A	-25	N/A
12/31/2013	0	-37	N/A	-22	N/A
9/30/2013	0	-31	N/A	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ARWR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ARWR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ARWR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ARWRDie Einnahmen des Unternehmens (50.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ARWRDie Einnahmen des Unternehmens (50.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ARWR in 3 Jahren voraussichtlich hoch sein wird

Arrowhead Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 14%

Consensus revenue estimates fall by 22%

Price target decreased by 7.5% to US$46.54

Consensus revenue estimates decrease by 19%, EPS upgraded

Price target decreased by 7.7% to US$52.23

Consensus revenue estimates fall by 10%

Recent updates

New major risk - Financial position

Consensus revenue estimates decrease by 14%

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Consensus revenue estimates fall by 22%

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Price target decreased by 7.5% to US$46.54

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceutical: Driving To Commercialization

Now 20% overvalued after recent price rise

Now 8.9% undervalued

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Now 26% overvalued

Now 21% overvalued

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals: Hoping Something Sticks

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Chief Financial Officer recently sold US$1.4m worth of stock

Chief Financial Officer notifies of intention to sell stock

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 25% overvalued after recent price rise

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Consensus revenue estimates decrease by 19%, EPS upgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Insider notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

CEO, President & Director notifies of intention to sell stock

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

CEO, President & Director notifies of intention to sell stock

Price target decreased by 7.7% to US$52.23

Consensus revenue estimates fall by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

New minor risk - Insider selling

Chief Medical Officer recently sold US$567k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New major risk - Revenue and earnings growth

CEO, President & Director notifies of intention to sell stock

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Financial Officer recently sold US$543k worth of stock

Chief Financial Officer notifies of intention to sell stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Consensus revenue estimates increase by 44%

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2023

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Consensus revenue estimates fall by 26%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis